Tag: cannabinoid pharmaceutical R&D
AusCann raises A$33.4m via share placementÂ
ASX-listed medical marijuana company AusCann has successfully raised A$33.4 million via a share placement to institutional and sophisticated investors from North America and Australia, including...
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
